The Safety of Omalizumab Therapy in a Patient With Severe Persistent Allergic Asthma and Hepatitis C

Antonicelli, Leonardo; Stagnozzi, Giorgia; Giuliodoro, Simona; Abbruzzetti, Alessandra; Massaccesi, Chiara

doi:10.1016/s1081-1206(10)60194-9

Cited by 7 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, three patients of our series with chronic hepatitis C are currently under treatment. Only two case reports on patients with chronic hepatitis C treated with omalizumab for asthma [28] or urticaria [29], with an observation period of 19 and 8 months, respectively, have been published to date. These reports showed that omalizumab is safe in terms of liver function.…”

Section: Discussionmentioning

confidence: 99%

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Bona

Fiorino

Taurino

et al. 2017

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Bona

Fiorino

Taurino

et al. 2017

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…The HCV infection did not seem to diminish the efficacy of omalizumab in this subset of patients. Only few cases of patients undergoing treatment with omalizumab with concurrent infection by hepatotropic virus, in particular, Hepatitis B Virus (HBV) and C virus, have been reported to date 21–23. In all patients, no side effects or infection worsening were documented, with concurrent substantial improvement of symptoms of asthma or urticaria.…”

Section: Discussionmentioning

confidence: 99%

<p>Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice</p>

Vollono

Piccolo

Lanna

et al. 2019

DDDT

View full text Add to dashboard Cite

IntroductionOmalizumab is a recombinant humanized anti-IgE monoclonal antibody, approved for patients affected by chronic spontaneous urticaria resistant to antihistamines. Although the clinical benefit of omalizumab has been established in several clinical trials, there are very little data about long-term treatment with this drug and real-life reports regarding its use in patients affected by comorbidities other than urticaria are lacking.ObjectivesTo assess omalizumab efficacy and safety in a heterogeneous population of patients affected by chronic spontaneous urticaria and several comorbidities in a real-world setting.Materials and methodsPatients affected by chronic spontaneous urticaria with weekly urticaria activity score >16 resistant to antihistamines were treated with omalizumab 300 mg injection as add-on to H1-antihistamines administered every 4 weeks for 6 months. Clinical assessment of weekly urticaria activity score, dermatology life quality index and blood tests were performed at baseline, 12, 24 and 52 weeks of treatment. Response was assessed based on reduction weekly urticaria activity score.ResultsThirty-two patients (22F; 10M) with a mean age of 52.4 years (range 27–72) affected by chronic spontaneous urticaria were enrolled. Comorbidities affecting our study population were divided into 6 categories: cardio-metabolic (77%), oncologic (19%), infectious (16%), allergic (45%) immunologic (41%) and others (18%). Omalizumab determined a satisfactory reduction of symptoms of chronic spontaneous urticaria and an amelioration of quality of life within our population. No relevant alterations regarding patients’ underlying conditions were encountered. This is the first study regarding the use of omalizumab for chronic spontaneous urticaria in a population of adult patients affected by several comorbidities, eg, cardio-metabolic, oncologic, infectious, allergic, immunologic and psychiatric diseases. Real-life data represent a valuable source of information about a drug’s safety and efficacy profile, especially in patients affected by different comorbidities that are widely diffused in Western countries.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

The Safety of Omalizumab Therapy in a Patient With Severe Persistent Allergic Asthma and Hepatitis C

Cited by 7 publications

References 8 publications

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

<p>Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice</p>

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About